Innovation and Product Development news (page 6)

• 

  3 June 2026

  Novo Nordisk launches Wegovy pill in UAE

  Oral semaglutide tablet now available in UAE for weight management; shows ~17% mean weight loss in trials and is approved to reduce certain cardiovascular risks.
• 

  3 June 2026

  Axens and Green Sky Capital partner to develop SAF plant in Egypt

  200,000 tpa SAF plant using lipid-based feedstocks and Axens' Vegan® HEFA, targeting production by end‑2027; will source used cooking oil locally and serve Mediterranean/African markets.
• 

  3 June 2026

  argenx: Efgartigimod shows sustained myositis benefit, maintained response in Sjogren’s with consistent safety

  ALKIVIA+ 52‑week data show sustained Total Improvement Score gains; RHO+ shows maintained response after switch to biweekly dosing; safety consistent across indications.
• 

  3 June 2026

  Mitsui Chemicals to expand MR™ high-refractive-index lens material capacity at Omuta Works

  New plant at Omuta Works to raise supply of MR™ high‑refractive‑index ophthalmic lens material, with commercial operations set for first half of 2029.
• 

  3 June 2026

  Sinopec mass-produces T1000 12K small‑tow carbon fiber

  First mass-produced wet-process T1000 12K small‑tow carbon fiber with single-tow strength >6.5 GPa and modulus >300 GPa, aimed at aerospace and other high-end uses.
• 

  2 June 2026

  Teijin Frontier develops polyester textile combining heat retention and high breathability

  Polyester textile pairs bulky raised nap for dead-air warmth with large-knit voids that double breathability and crimped-yarn moisture wicking; aimed at fall/winter 2027 sports and outdoor apparel.

• 

  2 June 2026

  QEMETICA sells salt assets to K+S and launches Resource Recovery unit

  Divests evaporated salt business for €350–€380m to fund a new Resource Recovery segment focused on waste-to-energy and energy security.
• 

  2 June 2026

  Evonik opens Asia Beauty Science & Innovation Center in Shanghai

  First integrated beauty R&D hub in Asia, combining biotech-led ingredient development, formulation, testing and a customer experience space to support brands across China and Asia.
• 

  2 June 2026

  ICARBON showcases advanced recycling at SET Tech Festival

  Presented advanced recycling and circular-economy solutions after SET100 selection; joined dena/Germany Trade & Invest workshop with 17 start-ups; visited EUREF‑Campus; pursuing international expansion.
• 

  2 June 2026

  Roche: FDA accepts priority‑review NDA for giredestrant in ER‑positive early‑stage breast cancer

  FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.
• 

  2 June 2026

  WuXi Biologics Repeats CDP Supplier Engagement A-List

  Named to CDP SEA A List again for supplier climate engagement; praised for governance, Scope 3 disclosure, SBTi-aligned targets (net-zero by 2050), supplier audits, training and incentives.
• 

  2 June 2026

  EAS Batteries launches ultra‑high‑power 22 Ah LFP cell using Asahi Kasei Acetolyte

  22 Ah LFP cell using acetonitrile electrolyte achieves 2,550 W/kg continuous, 3,760 W/kg 2s pulse, ~2,400 cycles at 5C/100% DoD; samples in customer evaluation; 46xxx format planned.
• 

  2 June 2026

  Dow showcases AI thermal-management materials at COMPUTEX 2026

  Showcases liquid and immersion cooling fluids, coolants for cold plates and facility loops, thermal interface materials, silicone packaging and hot‑melt solutions; keynote on cooling AI data centers.
• 

  1 June 2026

  Amgen: EC approves IMDYLLTRA (tarlatamab) for ES‑SCLC after platinum therapy

  EU marketing authorisation for tarlatamab as monotherapy for extensive‑stage small cell lung cancer after progression on platinum‑based chemo; Phase 3 showed survival gain.
• 

  1 June 2026

  Genentech: FDA accepts NDA for giredestrant after positive Phase III adjuvant results in early ER‑positive breast cancer

  lidERA Phase III: giredestrant reduced invasive recurrence/death by 30% (HR 0.70); 3‑yr iDFS 92.4% vs 89.6%. Priority review; PDUFA Nov 30, 2026; well tolerated in >4,100 pts.
• 

  1 June 2026

  Moderna & Merck: 5‑Year Data — Intismeran plus KEYTRUDA Reduces Recurrence in High‑Risk Resected Stage III/IV Melanoma

  5-year Phase 2b follow-up: combination showed 49% RFS reduction (HR 0.51), 59% DMFS reduction (HR 0.411); OS trend (HR 0.471). Safety consistent; increased neoantigen-specific T‑cell clonotypes
• 

  1 June 2026

  Dow and Univar Solutions agree long-term distribution of Decarbia low‑carbon products

  Long-term deal expands access to low‑carbon products with verified PCF certificates across beauty, home care, food, pharma and industrial markets; aids Scope 3 reductions.
• 

  1 June 2026

  Linde 2025 Sustainability Report

  2025: 10% absolute GHG cut vs 2021; 50% electricity from low-carbon/renewables; customers avoided ~98M tCO2e; conserved 1B+ gallons water; diverted 200M lbs waste; supported ~2,100 orgs, 400k people.
• 

  1 June 2026

  EEW updates Green Financing Framework; ISS-Corporate issues Second Party Opinion

  Publishes updated Green Financing Framework aligned with ICMA and LMA standards and the EU Taxonomy; covers energy, circular economy, carbon capture; independent SPO confirms quality
• 

  1 June 2026

  Roche to present obesity‑portfolio data at ADA 2026

  Phase II data show enicepatide and petrelintide yield meaningful weight loss with good safety/tolerability. Both advance toward Phase III; a Phase II combo trial starts mid‑2026
• 

  1 June 2026

  CATL opens world’s largest energy-storage testbed for real-world validation

  10-ha, RMB3bn Xiamen facility offers open station-level validation across five labs: 35kV/100MVA grid sim, 1kV–500kV HV tests, 20MW combustion, -50–100°C climate chambers, EMC for 40-ft containers
• 

  31 May 2026

  Lilly: Retevmo reduces recurrence/death risk by 83% as adjuvant in early‑stage RET‑fusion NSCLC

  Phase 3 LIBRETTO-432 randomized 151 early-stage RET‑fusion NSCLC patients; at 24‑month follow‑up EFS rates 92% vs 61% (treatment vs placebo). Safety: elevated ALT/AST manageable with dose changes.
• 

  31 May 2026

  Johnson & Johnson PROTEUS Phase 3: Perioperative ERLEADA reduces risk of metastasis or death by 20%

  Perioperative apalutamide + ADT (6 months pre/post-surgery) raised pCR/MRD to 8.9% vs 1%, delayed need for further therapy >6 vs 3.5 years, met dual primary endpoints; safety profile as expected.
• 

  31 May 2026

  Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

  Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.
• 

  29 May 2026

  EU advances carbon removals and carbon farming market

  CRCF Days launched rollout: certification schemes may seek CRCF recognition; Buyers’ Club to aggregate demand; removals and carbon‑farming methodologies near adoption; financing and de‑risking needed
• 

  29 May 2026

  Velocys, Tetracore sign MOU to evaluate modular GTL in Nigeria

  MOU to assess modular Fischer-Tropsch microFTL for Atakobo GTL in Ogun State - convert ~55 MMSCFD (~5,000 BPD) into diesel, Jet-A1 and naphtha to support domestic fuel supply.
• 

  29 May 2026

  Johnson & Johnson: RYBREVANT + LAZCLUZE yields 41‑month median OS in first‑line atypical EGFR‑mutant NSCLC

  CHRYSALIS-2 Phase1/1b (n=49): first-line atypical EGFR‑mutant NSCLC showed ORR 57%; 3‑yr OS 55%, 4‑yr OS 46%; 41% remained on treatment ≥2 years; safety consistent with prior reports.
• 

  29 May 2026

  Rompetrol Rafinare Q1 2026: Turnover up 8%, net profit achieved

  Q1: EBITDA $27.5M; March shutdown (700+ tasks) completed; Petromidia processed ~1.2Mt, white product yield 83.76%; domestic fuel share 66%; state contribution $577M
• 

  29 May 2026

  Johnson & Johnson: TECVAYLI improves PFS and OS in second-line multiple myeloma

  Phase 3 MajesTEC‑9: teclistamab cut progression/death risk 71% (HR 0.29) and death 40% (HR 0.60) vs PVd/Kd in early RRMM; higher ≥CR (65.9% vs 16.8%); infections and CRS increased
• 

  29 May 2026

  EU Innovation Fund Net‑Zero Call: 358 applications, €17.5bn requested (6× budget)

  Applicants across 27 countries submitted large/medium/small projects, pilots and cleantech manufacturing for energy‑intensive, carbon management, renewables and storage; results Oct 2026